Publications

Access hundreds of peer-reviewed papers published by neuroscientists using Cogstate technology.

An Online, Person-Centered, Risk Factor Management Program to Prevent Cognitive Decline: Protocol for A Prospective Behavior-Modification Blinded Endpoint Randomized Controlled Trial

Authors: Yen Ying Lim, Darshini Ayton, Stephanie Perin, Alexandra Lavale, Nawaf Yassi, Rachel Buckley, Christopher Barton, Loren Bruns, Renata Morello, Stephanie Pirotta, Emily Rosenich, Shantha M W Rajaratnam, Richard Sinnott, Amy Brodtmann, Ashley I Bush, Paul Maruff, Leonid Churilov, Anna Barker, Matthew P Pase , BetterBrains Research Group

Journal: Journal of Alzheimer's Disease

Year Published: 2021

Background Several modifiable risk factors for dementia have been identified, although the extent to which their modification leads to improved cognitive outcomes remains unclear. Objective The primary aim is to test the hypothesis that a behavior […]

Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2

Authors: Chris J Edgar, Eric Siemers, Paul Maruff, Ronald C Petersen, Paul S Aisen, Michael W Weiner, Bruce Albala, Alzheimer’s Disease Neuroimaging Initiative

Journal: Journal of Alzheimer's Disease

Year Published: 2021

Background There is a need for feasible, scalable assessments to detect cognitive impairment and decline. The Cogstate Brief Battery (CBB) is validated for Alzheimer’s disease (AD) and in unsupervised and bring your own device contexts. The […]

Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1

Authors: Karin S Walsh, Pamela L Wolters, Brigitte C Widemann, Allison Del Castillo, Maegan D Sady, Tess Inker, Marie Claire Roderick, Staci Martin, Mary Anne Toledo-Tamula, Kari Struemph, Iris Paltin, Victoria Collier, Kathy Mullin, Michael J Fisher, Roger J Packer

Journal: Neurology. Genetics

Year Published: 2021

Background and objectives Neurofibromatosis type 1 (NF1)-associated cognitive impairments carry significant lifelong morbidity. The lack of targeted biologic treatments remains a significant unmet need. We examine changes in cognition in patients with NF1 in the first […]

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV

Authors: Davide De Francesco, Xinzhu Wang, Laura Dickinson, Jonathan Underwood, Emmanouil Bagkeris, Daphne S Babalis, Patrick W G Mallon, Frank A Post, Jaime H Vera, Memory Sachikonye, Ian Williams, Saye Khoo, Caroline A Sabin, Alan Winston, Marta Boffito, Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study

Journal: PloS One

Year Published: 2021

Objectives To investigate the associations of plasma lamivudine (3TC), abacavir (ABC), emtricitabine (FTC) and tenofovir (TFV) concentrations with cognitive function in a cohort of treated people with HIV (PWH). Methods Pharmacokinetics (PK) and cognitive function (Cogstate, […]

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study

Authors: Kenichiro Sato, Ryoko Ihara, Kazushi Suzuki, Yoshiki Niimi, Tatsushi Toda, Gustavo Jimenez-Maggiora, Oliver Langford, Michael C Donohue, Rema Raman, Paul S Aisen, Reisa A Sperling, Atsushi Iwata, Takeshi Iwatsubo

Journal: Alzheimer's & Dementia

Year Published: 2021

Background Selecting cognitively normal elderly individuals with higher risk of brain amyloid deposition is critical to the success of prevention trials for Alzheimer’s disease (AD). Methods Based on the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease study […]

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch